newsfilter
← Latest News
GlobeNewswire·

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

KA

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose level in the